AndhraNews.net
Home » Business News » 2013 » August » August 13, 2013

Implant Sciences Sponsors Global Sports Summit


August 13, 2013 - Wilmington, MA

Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it sponsored and attended The Global Sports Summit, the first and only private meeting designed for leaders and owners of sports franchises from the NFL, NBA, MLB, NHL, MLS, European Football and other professional sports globally. On August 4th through 6th in Aspen, Colorado, Implant Sciences was a Session Host Sponsor where the Company met with the key decision makers and owners of global sports franchises.

"We see a very clear opportunity for our explosives trace detectors to meet the specific needs of security providers for sporting venues and events," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "At the different sports industry related conferences we have attended over the past few months we have provided product demonstrations and been in advanced discussions with the owners and managers of major sports venues and their security providers."

Implant Sciences' QS-H150 handheld explosives trace detectors have already provided fast, effective, user-friendly, radiation-free, non-invasive, and cost-efficient screening at some of the world's largest sporting events including the 2008 Beijing Olympics, the 2011 Summer Universiade Games in Shenzhen, China, and the 2012 Special Olympics in London.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

MarketWire

Comment on this story

Share